Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting mesothelin (MSLN). Upon binding MSLN on tumor cells, the CAR provides activation and costimulatory signaling, driving T‑cell cytotoxicity (perforin/granzyme release) and cytokine production to kill MSLN‑positive cancer cells, typically after lymphodepleting conditioning to enhance expansion.